Shares of Novavax (NVAX) rose 0.58% to close at $8.67 on Tuesday, ending a six-session slide. The stock has fallen around 18% between June 1 and June 8, compared to a 2.56% decline in the S&P 500 over ...

The new Novavax XBB.1.15 vaccine appears to have been knocked back for approval by the Therapeutic Goods Administration.

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the ...

Novavax's vaccine didn't enter the market until after the inoculations developed by Moderna and Pfizer had already taken dominant market shares. This meant it missed out on the biggest revenue ...

Why Novavax Stock Is Back on Investor Radars Novavax (NVAX) has been catching investor attention again after recent trading swings, with the stock closing at US$9.06 and showing mixed short term ...

Novavax's stock almost doubled on Friday after it announced the licensing agreement with Sanofi. Novavax on Friday said the deal allows the company to remove its "going concern" warning, which it ...

Novavax stock (NVAX) skyrocketed on Friday, nearly doubling on the news French drug and vaccine giant Sanofi (SNY) would invest $1.2 billion in a deal for Novavax's COVID-19 vaccine and take a ...

Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 12.3% in the afternoon session after the company reported better-than-expected first-quarter 2026 results.

Novavax earned approval for its COVID-19 vaccine, Nuvaxovid, in various countries. In the U.S., it is still under Emergency Use Authorization. However, the biotech is now seeking full approval.

Add Yahoo as a preferred source to see more of our stories on Google. Novavax, sold under the brand name Nuvaxovid, is a protein-based COVID-19 vaccine — the same technology used to develop many other ...

Novavax's protein-based shot is an option for COVID vaccination this season, joining refreshed formulas from Moderna and Pfizer. Jessica was a writer on the Wellness team, with a focus on health ...

Shares of Novavax jumped as much as 50% as Wall Street cheered a new multibillion-dollar deal with French drugmaker Sanofi that kicked off a dramatic turnaround for the struggling vaccine maker.